Eisai Corporation of North America Receives Action Letter on Fospropofol Disodium Injection for Sedation in Diagnostic or Therapeutic Procedures; FDA's Not Approvable Letter Outlines Pathway to ...
Woodcliff Lake, NJ - May 7, 2008 - Eisai Corporation of North America and its U.S. subsidiary, MGI PHARMA, INC., today announced that the U.S. Food and Drug Administration (FDA) Advisory Committee on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback